Blau Farmaceutica (BSP:BLAU3) Payments of Debt: R$-76 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:BLAU3 Blau Farmaceutica SA BSP:BLAU3
87 GF Score
Price R$9.02
GF Value R$11.22
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Blau Farmaceutica Payments of Debt?

Blau Farmaceutica BSP:BLAU3 +0.45% 87 Payments of Debt is R$-76 Mil as of Mar. 2026. GuruFocus rates BSP:BLAU3 with a GF Score™ of 87/100 and a GF Value™ of R$11.22 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Blau Farmaceutica's Payments of Debt for the three months ended in Mar. 2026 was R$-24 Mil.

Blau Farmaceutica's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was R$-76 Mil.

Blau Farmaceutica Payments of Debt Related Terms

Blau Farmaceutica Payments of Debt Historical Data

* Premium members only.

The historical data trend for Blau Farmaceutica's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Blau Farmaceutica Payments of Debt Chart

Blau Farmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -534.74 -85.93 -72.50 -50.00 -51.87

Blau Farmaceutica Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.87 -50.00 0.00 -1.87 -23.86
BSP:BLAU3
87GF Score
Blau Farmaceutica SA BSP:BLAU3
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Blau Farmaceutica Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of R$-76 Mil mean?
Blau Farmaceutica (BSP:BLAU3) has a Payments of Debt of R$-76 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Blau Farmaceutica and its competitors.
Is Blau Farmaceutica's Payments of Debt too high?
Blau Farmaceutica's current Payments of Debt is R$-76 Mil. Overall, Blau Farmaceutica has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Blau Farmaceutica's Payments of Debt compare to ZTS and UTHR?
Blau Farmaceutica's Payments of Debt of R$-76 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Blau Farmaceutica and its competitors. Blau Farmaceutica's current Payments of Debt is R$-76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blau Farmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Blau Farmaceutica (BSP:BLAU3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$11.22, compared to a current price of R$9.02 — trading 19.6% below its estimated fair value. The current Payments of Debt is R$-76 Mil. Blau Farmaceutica's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Blau Farmaceutica (BSP:BLAU3), the current Payments of Debt is R$-76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Blau Farmaceutica (BSP:BLAU3) Overvalued in 2026?

Based on GuruFocus' analysis, Blau Farmaceutica stock appears to be undervalued. The current stock price of R$9.02 is trading 19.6% below its estimated GF Value™ of R$11.22. GuruFocus considers Blau Farmaceutica to be Modestly Undervalued.

Key valuation signals for BSP:BLAU3:

  • Payments of Debt: R$-76 Mil
  • GF Value™: R$11.22 vs. price of R$9.02 (19.6% below fair value)
  • GF Score™: 87/100 with 6 warning signs

No single metric tells the full story. See the BSP:BLAU3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Blau Farmaceutica Business Description

Address Rodovia Raposo Tavares, No. 2833, Km 30.5, Barro Branco, Cotia, SP, BRA, 06705-030
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
87GF Score

Get the complete analysis for BSP:BLAU3

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$9.02
Price
R$11.22
GF Value